Details for Patent: 8,808,713
✉ Email this page to a colleague
Which drugs does patent 8,808,713 protect, and when does it expire?
Patent 8,808,713 protects BEVESPI AEROSPHERE and BREZTRI AEROSPHERE and is included in two NDAs.
This patent has one hundred and eighty-five patent family members in thirty-one countries.
Summary for Patent: 8,808,713
| Title: | Compositions for pulmonary delivery of long-acting .beta..sub.2 adrenergic receptor agonists and associated methods and systems |
| Abstract: | Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting .beta..sub.2 adrenergic receptor agonists via a metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium. |
| Inventor(s): | Vehring; Reinhard (Edmonton, CA), Hartman; Michael Steven (Millbrae, CA), Smith; Adrian Edward (Emerald Hills, CA), Joshi; Vidya B. (Redwood City, CA), Dwivedi; Sarvajna Kumar (Redwood City, CA) |
| Assignee: | Pearl Thereapeutics, Inc. (Redwood City, CA) |
| Application Number: | 12/790,605 |
|
Patent Claim Types: see list of patent claims | Composition; Delivery; Use; Process; |
More… ↓ |
Drugs Protected by US Patent 8,808,713
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | BEVESPI AEROSPHERE | formoterol fumarate; glycopyrrolate | AEROSOL, METERED;INHALATION | 208294-001 | Apr 25, 2016 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | ⤷ Subscribe | |||
| Astrazeneca Ab | BREZTRI AEROSPHERE | budesonide; formoterol fumarate; glycopyrrolate | AEROSOL, METERED;INHALATION | 212122-001 | Jul 23, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,808,713
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2435025 | ⤷ Subscribe | 300995 | Netherlands | ⤷ Subscribe |
| European Patent Office | 2435025 | ⤷ Subscribe | PA2019014 | Lithuania | ⤷ Subscribe |
| European Patent Office | 2435025 | ⤷ Subscribe | 122019000068 | Germany | ⤷ Subscribe |
| European Patent Office | 2435025 | ⤷ Subscribe | 2019C/532 | Belgium | ⤷ Subscribe |
| European Patent Office | 2435025 | ⤷ Subscribe | LUC00124 | Luxembourg | ⤷ Subscribe |
| European Patent Office | 2435025 | ⤷ Subscribe | CA 2019 00032 | Denmark | ⤷ Subscribe |
| European Patent Office | 2435025 | ⤷ Subscribe | 36/2019 | Austria | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
